Roche’s new influenza drug Xofluza can dramatically prevent the spread of the virus when used as a preventive therapy, according to new phase 3 data. Xofluza (baloxavir marboxil) is already ...

Because of the high number of flu patients being prescribed this drug, some pharmacies are experiencing a shortage. According ...

The FDA has approved a new use for Xofluza (baloxavir marboxil) from Roche’s Genentech unit, to prevent people developing flu after coming into contact with an infectious person.

The lead medication being prescribed is Xofluza. According to Doctor Lindsey Clark with the Mississippi Baptist Medical Center, Xofluza is a common medication prescribed to treat the flu.

Roughly a quarter of 38 viral samples from people treated with Xofluza had mutations in their genomes that made the pathogens less susceptible to the drug. Kerry served as The Scientist’s news ...

The weekly report from the Arkansas Department of Health shows flu activity at a very high level for the week ending Feb. 1.

“This could be a breakthrough in the way that we treat influenza.” Data from the drugmaker, Shionogi, show that while Xofluza works days faster than Tamiflu in stopping the flu virus, symptoms wrap up ...